50 results about "Mammalian tissue" patented technology

An inspection method is disclosed to inspect a fluorescent image of a mammal tissue that comprises an array of pixels having respective fluorescent signal values. A reference value is determined, such that a second number of fluorescent signal values, as a predetermined fraction of a first number of fluorescent signal values, is smaller than or equal to the reference value and the remainder of the first number of fluorescent signal values exceeds the reference value. The method comprises, in the second number of fluorescent signal values, determining an average fluorescent signal value and a standard deviation of those fluorescent signal values. An image segmentation is performed to distinguish in the fluorescent image a target region to denote a portion in the mammal tissue that is identified as tumorous tissue and a reference region to denote a remaining portion in the mammal tissue.

Microneedle patches that include a backing layer, and an array of microneedles extending from the backing layer. wherein the microneedles each include a core portion which includes a drug, and a shell portion and a cap portion, wherein the core portion is encapsulated within the shell portion and cap portion. The microneedles are configured to be inserted into mammalian tissue and then separate from the backing layer. The shell portion and / or the cap portion is biodegradable and delays release of the drug for an extended period.

Wound management assemblies, kits, and methods are disclosed. A wound management assembly can include a guidewire and a wound matrix compressed onto the guidewire. The wound matrix can optionally be derived from a perfusion-decellularized mammalian tissue or organ. The assembly can further include a tamp member positioned on the guidewire, proximal to a position of the wound matrix. The assembly can be delivered to a desired location within a wound bed using the guidewire or using an introducer set included in a kit. A method can include navigating the wound management assembly to the entrance of the wound bed, using the tamp member to distally urge the wound matrix into the wound bed, and subsequently removing the tamp member, the guidewire, and a sheath if used.

The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and / or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following:or a pharmaceutically acceptable salt thereof,or a pharmaceutically acceptable salt thereof,or a pharmaceutically acceptable salt thereof,wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.

A microneedle patch comprising a backing layer and an array of microneedles extending from the backing layer wherein the microneedles each comprise: a core portion comprising a drug; and a shell portion and a cover portion, wherein the core portion is encapsulated within the shell portion and the cover portion. The microneedles are configured to be inserted into mammalian tissue and then separated from the backing layer. The shell portion and / or the cap portion are biodegradable and delay release of the drug for an extended period of time.

The invention provides novel methods for analyzing (e.g., imaging) drugs in mammalian tissues, and methods for identifying drug targets and analyzing drug-target interactions.

The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue via 18F-labeled peptide ligands disclosed herein.

Microneedles for drug delivery that include a wax or other meltable material and methods of making and using such microneedles are disclosed. A microneedle patch includes a backing layer; and an array of microneedles extending from the backing layer, wherein the microneedles each include a distal tip portion that includes a drug, and the microneedles are configured to be inserted into mammalian tissue and, at least a portion of each of the microneedles is configured to melt in the mammalian tissue. In some other cases, melt materials are used during manufacturing of the microneedles but do not melt in the skin.

Described herein are systems, methods, and interconnecting porous hydrogel blocks for generating mammalian tissue. A block may comprise a three-dimensional continuous polymeric matrix with a network of microporous cavities, and may be configured to interconnect with at least one other block. A system may comprise a plurality of blocks configured to interconnect to form a scaffold configured to cultivate one or more cell types organized into stratified layers. A method may comprise acquiring a plurality of blocks, interconnecting the blocks to form a scaffold configured to cultivate one or more cell types organized into stratified layers, and seeding at least one block with at least one cell type adherent to the block. Embodiments may comprise perfusing at least one block with culture media and / or harvesting mammalian tissue generated.

Aspects and embodiments relate to a tissue mimicking material, a clinical phantom including a tissue mimicking material and a method of manufacture of a tissue mimicking material. According to one aspect there is provided: a tissue mimicking material comprising: an alginate matrix; and an ablation-sensitive agent distributed through the alginate matrix. Aspects and embodiments recognise that use of an alginate matrix as a base for a tissue mimicking material provides relatively low cost material having various physical properties and characteristics which can be tuned or refined to simulate the characteristics of a mammalian tissue which the alginate matrix is intended to mimic. In relation to use of an alginate material in the context of thermal and / or pulsed electric field ablation simulation, it has been recognised that an alginate material may be appropriately temperature stable and not degrade upon exposure to high, or low, ablation temperatures, or upon exposure to ablation levels of pulsed electric field. Distribution of an appropriately selected ablation-sensitive agent through the alginate material may allow a change caused by application of an ablation technique to the tissue mimicking material to be observed.

A method of sterilizing biological tissue such as soft mammalian tissue that can be used to make bioprosthetic devices is disclosed. The method comprises contacting biological tissue with a bioburden reduction mixture, contacting biological tissue with a tissue drying mixture, and thereafter sterilizing the dry tissue with supercritical carbon dioxide. Prior to sterilizing the biological tissue with supercritical carbon dioxide, the biological tissue is placed under vacuum and, in some embodiments, is treated with a vaporized microbicide. Bioprosthetic devices made using the methods disclosed herein include bioprosthetic heart valves, biological tissue derived vascular grafts or vessels, and surgical tissue patches.

The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and / or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following:or a pharmaceutically acceptable salt thereof,or a pharmaceutically acceptable salt thereof,or a pharmaceutically acceptable salt thereof,wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.

An apparatus for isolating stems cells from extracted mammalian tissue comprising:a portable hollow casing having fixed dimensions and a sized internal spatial volume;a filter housed and contained within said sized internal spatial volume, wherein said filter captures particles in said extracted mammalian tissue having a diameter of about 5 to 10 microns or more and allows particles in said extracted mammalian tissue having a diameter of less than about 5 to 10 microns to pass through;a first channel to which a container holding said extracted mammalian tissue can attach, and through which said extracted mammalian tissue is input into the hollow casing;wherein a stem cell collection chamber can attach to said first channel, and the particles having a diameter of about 5 to 10 microns or more are output from the hollow casing through said first channel and collected in the stem cell collection chamber; anda second channel to which a remnant collection chamber can attach, and through which the particles having a diameter of less than about 5 to 10 microns are output from the hollow casing and collected in the remnant collection chamber.

Provided is use of a protein synthesis inhibitor in promoting regeneration and repair capacity of mammal tissues or complex structures or organs. The protein synthesis inhibitor is a small molecule compound, from any of cycloheximide or an Amaryllidaceae extract, capable of promoting regeneration of mammal tissues and organs.

Disclosed herein are devices, systems, and methods for applying and / or delivering topical compounds (e.g., topical medications) to the surface of mammalian tissue (e.g., skin, mucous membranes, and / or other tissue surfaces). Specifically, disclosed embodiments include a device that is configured to connect to one or more types of known syringes, and, in particular, to one or more types of known syringe tips. At least one embodiment of the device comprises a cap and a membrane, where the cap includes an open connector end for engaging and / or attaching to a syringe via a syringe tip, a delivery end opposite to the connector end, and a cap body disposed between, and connecting, the connector end and the delivery end. The delivery end can further be connected to the membrane by, for instance, inserting one end of the membrane into the delivery end.

A prosthetic heart valve includes a support structure and a valve assembly disposed within the support structure, the valve assembly including a plurality of leaflets. Each leaflet is formed from a predetermined leaflet material. Some leaflet materials include a metal body with a plurality of openings. The metal body may be coated with a polymer. Other leaflet materials include natural mammalian tissue subjected to a plastination preservation process.

The invention relates to the field of dressings, in particular to a preparation method and application of an acellular biological matrix dressing. The decellularized biological matrix dressing is prepared by the following steps: decellularizing mammalian tissues, sequentially carrying out ion induction and crushing to obtain a crushed product, carrying out surface finishing and vacuum drying on the crushed product, and mixing to obtain the decellularized biological matrix dressing. The obtained acellular biological matrix dressing has a rougher surface and a more uniform roughness degree, so that the stability of the final product acellular biological matrix dressing and the capability of promoting cell adhesion are improved. When in use, the particle can be directly applied to various wounds, the complexity of using the particle in the prior art is reduced, and the particle can be directly covered on full-thickness skin defect wounds (such as deep wet wounds) and superficial wounds (such as dry epidermis injury).

Devices for carrying out subperiosteal minimally invasive jaw bone augmentation and reconstruction procedures, to develop a passageway and surgical site in a concealed area of patient tissue, where the surgical site is not exposed. The devices have shanks with specially configured tips to facilitate maneuvering the device through mammalian tissue to develop a tunnel in the tissue and a remote surgical site within the tissue. The device tips have one or more peripheral cutting surfaces that direct the positioning of the tunnel formation when the instrument handle is manipulated, e.g., by rotation, angular, forward or rearward motion. Embodiments of the devices are configured with tips that have a wide spread for cutting and elevating tissue, and with tips that may be maneuvered to condense bone graft material being implanted at a surgical site concealed within the tissue.

There is provided a liquid injection device (10) comprising an injection tube (12), wherein the injection tube (12) extends in a hollow tip (14) with a plurality of openings (16). At least three circumferentially displaced openings (16) are provided around the hollow tip (14) below an edge (15) of the hollow tip (14) and the hollow tip (14) is provided with a non-cutting edge. There is also provided a method for performing heat therapy of mammalian tissue, comprising the steps: inserting an injection tube (12) extending in a hollow tip (14) in a selected position in the tissue, injecting a liquid including at least one anesthetic and adrenaline heated to a temperature of at least 37° C through the injection tube and through a plurality of openings (16) 0 below an edge (15) of the hollow tip (14) into the mammalian tissue.

The invention provides novel methods for analyzing (e.g., imaging) drugs in mammalian tissues, and methods for identifying drug targets and analyzing drug-target interactions.

To provide a biological treatment for intervertebral discs that can aid in repairing or replacing a subject's intervertebral disc.SOLUTION: The present invention relates to discogenic cell populations, methods of deriving the same, and methods of using the same. The discogenic cell population includes at least one cell derived from mammalian disc tissue and grown in vitro in anchorage-independent culture. The discogenic cell populations may be used to restore or regenerate damaged, diseased, or missing intervertebral discs of a subject. The discogenic cell populations can be derived from and administered or implanted into a subject, or may be derived from an unrelated donor.SELECTED DRAWING: None

The present invention relates to methods for large tissue labeling, transparentizing and / or imaging using labeling agents (e.g., antibodies), as well as uses and products related thereto. The invention includes, inter alia, methods of preparing animal tissue for fluorescence microscopy, animal tissue obtainable by said methods, methods of analyzing said animal tissue, and methods for detecting transfers, analyzing the biological distribution of biopharmaceutical drugs, and analyzing the biological distribution of nanoparticles. The methods of making animal tissue according to the present invention encompass whole body marking, transparentizing and imaging methods. The method of the invention is advantageous in that: They allow for visualization of individual cells within mammalian tissue, including the entire mouse body or other large tissue, tumor metastasis at the single cell level, and visualization of the distribution of biopharmaceutical drugs (e.g., tumor metastasis, tumor metastasis, tumor metastasis, tumor metastasis, tumor metastasis, tumor metastasis, tumor metastasis, tumor metastasis, tumor metastasis, tumor metastasis, tumor metastasis, tumor metastasis, tumor metastasis, tumor metastasis, tumor metastasis, tumor metastasis, the distribution of cancer targeted therapy antibodies in a whole animal (e.g., a complete mouse).

The invention relates to the field of biological materials, and particularly discloses an acellular matrix material and a preparation method thereof. The preparation method of the material comprises the following steps: extracting a tissue material of a mammal, carrying out decellularization treatment on the tissue material to obtain a decellularized tissue material, freeze-drying the tissue material, and crushing to obtain an animal-derived decellularized matrix; resuspending an animal-derived acellular matrix in water, mixing the animal-derived acellular matrix with the modified epoxidized chitosan solution, adding transglutaminase for reaction, and freeze-drying the obtained product to obtain the acellular matrix material. According to the method, the animal-derived acellular matrix and the modified epoxidized chitosan are cross-linked, so that the biocompatibility of the acellular matrix can be improved, and immunological rejection can be reduced; meanwhile, as the cross-linking reaction is biological cross-linking under the action of transglutaminase, bioactive factors contained in the acellular matrix are not easy to damage in the cross-linking process, and the biological activity and safety are better.

The present application relates to, in certain aspects, methods and compositions for imaging mammalian brain tissue via detection of multiple different epitope tags delivered via a plurality of vectors. Certain aspects provided herein relate to binder sets for the multiple different epitope tags, and resulting compositions.

The invention discloses application of CCL2 in promoting organ or tissue regeneration and delaying senescence. According to the invention, a plurality of tissue damage regeneration models are utilized, the damage repair characteristics and common regulation and control mechanisms of eight tissues of mammals are systematically analyzed in combination with single cells, and biomarkers and potential intervention targets related to damage repair are deeply excavated by comparing the damage repair differences of young and old tissues, so that the damage repair of the mammals is realized. And a theoretical basis is provided for regeneration function evaluation, early warning and accurate intervention. Meanwhile, the invention also finds that the CCL2 can be used as a key target for improving the regeneration capacity of the senile tissues, which is beneficial to exploring a novel intervention means and developing a new strategy for regulating and controlling regeneration, delaying senescence and preventing and treating senescence-related diseases.

Compositions and methods for providing the hybrid benefit of treating biofilms on the surface of mammalian tissue, especially biofilms that occur in association with chronic wounds and burns, and simultaneously providing an antiseptic cleansing and maintenance of the stratum corneum of the tissue and other tissue surfaces, and an opportunity for the tissue to improve by engaging its own natural barrier and immunological defense properties. The compositions and methods prevent the re-establishment of biofilms by facilitating the reduction or eradication of the pathogen producing the biofilm before the biofilm can be established.

The present invention provides novel methods for analyzing (eg, imaging) drugs in mammalian tissues, as well as methods for identifying drug targets and analyzing drug-target interactions.

A thermally representative phantom mammalian manikin assembly is provided. The assembly can include a cover portion representative of mammalian tissue partially enclosing a thermal cavity having a thermally representative material therein. The cover portion can have an opening with a cap extending across the opening and configured to further enclose the thermal cavity. The cap can have an aperture extending therethrough to receive a device extending through the aperture and into the thermally representative material within the thermal cavity. The device can be a thermocouple configured to measure a temperature of the thermally representative material. In assemblies representing mammalian limbs, the assembly can further include a second thermal cavity representing an additional portion of the limb, e.g., thermally representative upper and lower leg cavities.

The present invention provides for methods and at least partially automated devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. Tissue regeneration in humans is extremely limited and constitutes a major challenge to the repair of damaged organ function. Wound treatment is a typical area where tissue regeneration is required. Wounds (lacerations or openings) in mammalian tissue can result in tissue disruption and coagulation of the microvasculature at the wound face.

Provided herein are compounds useful for inducing biostasis. Also provided are pharmaceutical compositions comprising the compounds, kits comprising the compounds, methods of inducing biostasis in subjects, biological samples and cells, and methods of preserving biological samples (e.g., mammalian tissue) by a compound or composition described herein.